STAA · STAAR Surgical Company · Stock research

Current Thesis

STAAR Surgical sells the EVO/EVO+ ICL, an implantable collamer lens marketed as a permanent alternative to LASIK, with revenue concentrated in China. The frame has now rotated twice: first out of a merger-arbitrage special situation, and as of this week out of the clean China-recovery momentum leg that replaced it. On July 16 (after the close) the company pre-announced Q2 net sales "in excess of $90 million" against $44.3M in Q2 2025 — a +103% YoY figure that landed roughly on the $90.2M consensus and above Canaccord's $88.4M model. The market sold it: shares gapped from a $28.98 close to a $26.75 open on July 17 and finished $26.44, down 8.76%, cutting through the $29.43 50-day. The reason the tape disagreed with the headline is sequential. Q1 2026 printed $93.52M; Q2 came in below that, with EMEA down a low-single-digit percentage on Middle East conflict disruption offsetting sequential China growth, double-digit Americas gains, and double-digit EMEA growth excluding the Middle East. The comp math also turns here — Q2 2025's $44.3M was the destocking trough, so the triple-digit YoY headlines end with this quarter. What remains is a mid-cap ophthalmic device business at roughly $1.3B market cap, $290M TTM revenue, still loss-making on a TTM basis (-$21.03M, EPS -$0.42), trading at a 34x forward multiple with a broken 50-day and a consensus target ($27.81 from the eleven-analyst Hold-skewed panel; $29.67 on the broader Buy tally) sitting at or under spot. That combination does not support a fresh momentum entry.

Bullish and bearish views on STAAR Surgical Company

The model's bull view on STAAR Surgical Company (STAA), in brief: Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16) — over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate. The bear view: An in-line pre-announcement drew an 8.8% selloff. Both cases follow in full.

Bull Case

• Q2 2026 preliminary net sales exceeded $90M vs $44.3M a year prior (announced 2026-07-16) — over 103% YoY, in line with the $90.2M consensus and ahead of Canaccord's $88.4M estimate.
• China grew sequentially in Q2 on normalized distributor operations. This is the second consecutive quarter of clean channel behaviour after the 2025 destocking that took shares to a $15.59 low. Q1 China contributed $47.4M of $93.5M total.
• Q1 2026 (2026-05-13) was a genuine beat: net sales $93.52M (+119.6% YoY), non-GAAP EPS $0.29 against $0.08 consensus, GAAP $0.10 against roughly $0.05, with net income swinging to +$5.2M from -$54.2M.
• The weakness is geographic and identifiable, not demand-side. EMEA excluding the Middle East grew double digits; the Americas grew double digits. The drag is one region under active conflict disruption.
• Wedbush reiterated Outperform with a $40 target on 2026-07-16, holding the thesis it upgraded to on 2026-05-29 (from Neutral, PT lifted from $26) that STAAR is at or near a full China rebound inflection.
• Balance sheet gives the recovery runway: quick ratio 4.31, current ratio 5.12, debt-to-equity 0.09.
• A ~31% holder with three board seats. Broadwood Partners killed Alcon's $30.75/share ($1.6B) bid at the January 6 2026 special meeting arguing a standalone path worth materially more, then took board representation via the January 15 cooperation agreement alongside Yunqi Capital (6.5%). That block is not a seller here.

Bear Case

• An in-line pre-announcement drew an 8.8% selloff. Companies pre-announce to control a narrative; the market's response to a headline that met consensus indicates positioning was leaning on a sequential acceleration that did not arrive. Q1 $93.5M into Q2 ">$90M" is a sequential step down.
• The easy comparisons expire now. Q2 2025's $44.3M was the destocking trough. From Q3 2026 the base normalizes, and triple-digit YoY growth headlines stop doing the narrative work.
• Price structure has broken. The 50-day at $29.43 is now overhead resistance rather than support; the 200-day sits at $23.80. The stock is 26% off its $35.87 52-week high with no reclaim attempt yet.
• The M&A binary is spent. The June 18 2026 annual meeting — the same date Broadwood's standstill on demanding a special meeting expired — produced director re-elections, a 3.9M-share equity plan increase, auditor ratification and a passing say-on-pay vote, with no sale process, strategic review, or special-meeting demand on the record. A month later there is still nothing.
• Leadership has been interim for six months. Warren Foust (President/COO) and Deborah Andrews (CFO) have run the company as co-CEOs since February 1 2026, each on a $375,000 RSU grant, while a permanent-CEO search stays open. Chair Yeu and ex-CEO Farrell left the board in January.
• Analyst dispersion is a warning, not an opportunity. The panel splits 3 Buy / 6 Hold / 2 Sell, with Wells Fargo at $25, Canaccord at $32 and Wedbush at $40. Consensus $27.81 is a few percent above spot; the $40 case requires the China ramp to re-accelerate, and the $25 case is already nearly satisfied.
• China remains over half the revenue base with Q1 trade receivables running a higher share (57%) than sales (51%). Collectability and sell-in timing stay live risks that a single soft quarter would expose.
• Still unprofitable on a trailing basis — -$21.03M net income, -$0.42 EPS — against a 34x forward multiple.

Setup & Price Structure

Shares closed $26.44 on 2026-07-17 after a gap-down from $28.98, breaking the $28–32 post-Q1 consolidation and losing the $29.43 50-day in a single session. The 200-day at $23.80 is the next structural reference, roughly 10% lower, and it is still rising — the range between here and there is where the tape decides whether this is a shakeout inside an uptrend or the start of a rollover. Beta is 1.23; institutional ownership is 96.7%, so float mechanics amplify repositioning around news like this. A momentum framework has nothing to buy in a name that just lost its 50-day on a fundamental release; the constructive version requires a higher low above the 200-day and a reclaim of $29.43 on volume. Averaging into the gap because Wedbush carries a $40 target is exactly the wrong instinct here — the target predates the sequential deceleration.

Catalyst Calendar (next 30 days)

• 2026-08-12 — Q2 2026 full results and conference call (company-stated date; note some data vendors carry 2026-08-05, treat the company release as authoritative). The revenue line is already known; the variables are gross margin against the ~75% framing, the 2026 spend plan near $225M, China trade receivables versus sell-in, and any full-year commentary.
• 2026-08-14 — Q2 2026 13F deadline. Broadwood's and Yunqi's June-quarter positioning becomes visible; continued accumulation versus a pause is the cleanest read on whether the standalone case still has its anchor holder behind it.
• Undated, live — permanent CEO announcement. The search has been open since February 2026; a credible external hire is the single event most likely to re-rate the standalone narrative.
• Undated, ongoing — Middle East conflict headlines. Management explicitly warned that intensifying geopolitical and macroeconomic pressure could weigh on future revenue growth, making EMEA a recurring quarterly swing factor.

What Would Change Our Mind

The constructive case turns back on if the August 12 print shows China accelerating sequentially with gross margin at or above 75% and trade receivables falling back toward the sales share, and price reclaims the $29.43 50-day on expanding volume — that would reframe the July 17 gap as a liquidation flush rather than a trend break. A permanent CEO with refractive-surgery commercial credentials, or a fresh Broadwood open-market tranche disclosed via Form 4 into this weakness, would each add weight. Conversely, a Q2 report showing China net sales flat-to-down sequentially, or EMEA weakness spreading beyond the Middle East, confirms that the recovery leg has already been priced and paid out.

Correlation Notes

STAA trades as a China-elective-procedure proxy wearing a medtech label. Its correlation is less with the US medtech complex than with Chinese discretionary consumption and premium elective-surgery volumes — the same demand pool that drove the 2025 destocking collapse. Peer read-throughs come from Alcon (the failed acquirer and the dominant refractive/cataract franchise), Bausch + Lomb and Glaukos on ophthalmic device demand, and RxSight on premium-lens elective spending. Because more than half of revenue clears through Chinese distributors, the name also carries a channel-inventory factor absent from most US-domiciled device peers: reported sales can lead or lag true implant volume by a quarter, which is what made both the 2025 crash and the 2026 recovery larger than end-demand justified. Ownership concentration — Broadwood at ~31%, Yunqi at 6.5%, institutions at 96.7% — means the effective float is small and moves are exaggerated in both directions on position changes.